V1a arginine vasopressin receptor disruptions, compositions and methods relating thereto
OwnerThomas J. Brennan, Qin Zhanginventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods relating to the characterization and function of V1a vasopressin receptor. Specifically, the present invention provides transgenic animals comprising disruptions in a V1a vasopressin receptor gene and methods of treating diseases conditions, such as schizophrenia, diabetes and inflammatory bowel disease. The present invention further relates to agents that modulate V1a vasopressin receptor and methods of screening for agents that modulate V1a vasopressin receptor for the treatment of diseases and conditions such as schizophrenia, diabetes and inflammatory bowel disease.
Claims40
A transgenic mouse comprising a disruption in a V1a vasopressin receptor gene.
A transgenic mouse comprising a disruption in a V1a vasopressin receptor gene, wherein there is no native expression of endogenous V1a vasopressin receptor gene.
A method of producing a transgenic mouse comprising a disruption in a V1a vasopressin receptor gene, the method comprising:
- (a) providing a murine stem cell comprising a disruption in a V1a vasopressin receptor gene;
- and
- (b) introducing the murine stem cell into a pseudopregnant mouse, wherein the pseudopregnant mouse gives birth to a transgenic mouse.
A targeting construct comprising:
- (a) a first polynucleotide sequence homologous to at least a first portion of a V1a vasopressin receptor gene;
- (b) a second polynucleotide sequence homologous to at least a second portion of a V1a vasopressin receptor gene;
- and
- (c) a selectable marker located between the first and second polynucleotide sequences.
A cell comprising a disruption in a V1a vasopressin receptor gene.
A method of identifying an agent that modulates prepulse inhibition, the method comprising:
- (a) contacting a test agent with V1a vasopressin receptor;
- and
- (b) determining whether the agent modulates V1a vasopressin receptor.
A method of identifying an agent that modulates prepulse inhibition, the method comprising:
- (a) administering a test agent to an animal exhibiting decreased prepulse inhibition;
- and
- (b) determining whether the agent modulates the decreased prepulse inhibition.
A method of identifying a potential therapeutic agent for the treatment of schizophrenia, the method comprising:
- (a) administering the potential therapeutic agent to a transgenic mouse comprising a disruption in a V1a vasopressin receptor gene;
- and
- (b) determining whether the potential therapeutic agent modulates schizophrenia, wherein modulation of schizophrenia identifies a potential therapeutic agent for the treatment of schizophrenia.
A method of identifying a potential therapeutic agent for the treatment of schizophrenia, the method comprising:
- (a) contacting the potential therapeutic agent with V1a vasopressin receptor;
- (b) determining whether the agent modulates V1a vasopressin receptor, wherein modulation of V1a vasopressin receptor identifies a potential therapeutic agent for the treatment of schizophrenia.
A method of identifying a potential therapeutic agent for the treatment of diabetes, the method comprising:
- (a) contacting the potential therapeutic agent with V1a vasopressin receptor;
- (b) determining whether the agent modulates V1a vasopressin receptor, wherein modulation of V1a vasopressin receptor identifies a potential therapeutic agent for the treatment of diabetes.
A method of identifying a potential therapeutic agent for the treatment of inflammatory bowel disease, the method comprising:
- (a) administering the potential therapeutic agent to a transgenic mouse comprising a disruption in a V1a vasopressin receptor gene;
- and
- (b) determining whether the potential therapeutic agent modulates a symptom of inflammatory bowel disease, wherein modulation of the symptom of inflammatory bowel disease identifies a potential therapeutic agent for the treatment of inflammatory bowel disease.
A method of identifying a potential therapeutic agent for the treatment of inflammatory bowel disease, the method comprising:
- (a) contacting the potential therapeutic agent with V1a vasopressin receptor;
- (b) determining whether the agent modulates V1a vasopressin receptor, wherein modulation of V1a vasopressin receptor identifies a potential therapeutic agent for the treatment of inflammatory bowel disease
A method of evaluating a potential therapeutic agent capable of affecting a condition associated with a mutation in a V1a vasopressin receptor gene, the method comprising:
- (a) administering the potential therapeutic agent to a transgenic mouse comprising a disruption in a V1a vasopressin receptor gene;
- and
- (b) evaluating the effects of the agent on the transgenic mouse.
A method of evaluating a potential therapeutic agent capable of affecting a condition associated with a mutation in a V1a vasopressin receptor gene, the method comprising:
- (a) contacting the potential therapeutic agent with V1a vasopressin receptor;
- (b) evaluating the effects of the agent on the V1a vasopressin receptor.
A therapeutic agent for treating schizophrenia, wherein the agent modulates V1a vasopressin receptor.
A therapeutic agent for treating schizophrenia, wherein the agent is an agonist of V1a vasopressin receptor.
A therapeutic agent for treating diabetes, wherein the agent modulates V1a vasopressin receptor.
A therapeutic agent for treating diabetes, wherein the agent is an antagonist of V1a vasopressin receptor.
A therapeutic agent for treating inflammatory bowel disease, wherein the agent modulates V1a vasopressin receptor.
A pharmaceutical composition comprising V1a vasopressin receptor.
A method of preparing a pharmaceutical composition for a condition associated with a function of V1a vasopressin receptor, the method comprising:
- (a) identifying a compound that modulates V1a vasopressin receptor;
- (b) synthesizing the identified compound;
- and
- (c) incorporating the compound into a pharmaceutical carrier.
A method of treating schizophrenia, the method comprising administering to a subject in need a therapeutically effective amount of an agent that modulates a V1a vasopressin receptor.
A method of treating diabetes, the method comprising administering to a subject in need a therapeutically effective amount of an agent that modulates a V1a vasopressin receptor.
A method of treating inflammatory bowel disease, the method comprising administering to a subject in need a therapeutically effective amount of an agent that modulates a V1a vasopressin receptor.
Phenotypic data associated with a transgenic mouse comprising a disruption in a V1a vasopressin receptor gene, wherein the phenotypic data is in an electronic database.
Dependencies are inferred from the claim text.